American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR
Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.
First ACC/AHA acute pulmonary embolism guidelines include new categories for risk stratification
The new guidance, the first of its kind, focuses on the importance of making a prompt diagnosis and providing care as quickly as possible. While some PE patients with mild cases can be discharged early, others may require an immediate catheter-based intervention or surgery.
How hypertension during pregnancy impacts a woman's long-term cardiovascular health
Emerging research suggests that the early postpartum period may represent a critical window for influencing a woman's long-term cardiovascular health.
Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay
Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.
TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR

Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.

First ACC/AHA acute pulmonary embolism guidelines include new categories for risk stratification

The new guidance, the first of its kind, focuses on the importance of making a prompt diagnosis and providing care as quickly as possible. While some PE patients with mild cases can be discharged early, others may require an immediate catheter-based intervention or surgery.

Michael Honigberg, MD, MPP, a preventive cardiologist and cardiovascular researcher at Massachusetts General Hospital, explains how preeclampsia and gestational hypertension during pregnancy can elevate cardiovascular risks later in life and how to best manage these patients.

How hypertension during pregnancy impacts a woman's long-term cardiovascular health

Emerging research suggests that the early postpartum period may represent a critical window for influencing a woman's long-term cardiovascular health.

money cost cutting Medicare scissors dollar economics

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay

Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.

iron bioresorbable scaffold Biotyx Medical

Ultrathin iron bioresorbable scaffold shows promise in first randomized trial

An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.

Boston EP Party: Medtech companies share new electrophysiology data at AF Symposium 2026

AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations.